CDMO Cambrex snatches Halo Pharma, getting 2 plants and 425 employees

Halo Pharma plant
This plant in Montreal is one of two that Cambrex will get with its $425 million deal to buy Halo Pharma. (Cambrex)

There is more M&A action in the CDMO arena this week as New Jersey-based Cambrex has struck a deal to buy Halo Pharma, picking up two manufacturing facilities in the process.

Cambrex Monday said it has agreed to pay $425 million to buy the dosage-form CDMO from SK Capital, a firm with a number of CDMO holdings.

“Halo’s expertise in oral solids, liquids, creams and ointments fits well with our small molecule API business and brings a substantial new customer base and pipeline of small molecule products,” Steve Klosk, Cambrex CEO said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Halo agrees to buy Teva's Montreal facility

Halo operates manufacturing sites in Whippany, New Jersey, and Montreal, Québec, Canada, comprising a total of 430,000 square feet of plant space. Its 450-person workforce will join Cambrex’s 1,200 employees across the United States and Europe. Cambrex said Halo is expected to generate more than $100 million in annual revenue in 2018.

SK Capital has been in the midst of a lot of consolidation in the CDMO market. A year ago Perrigo sold off its active pharmaceutical business to the investment group for $110 million.

Other deals include the recent June deal by France’s Novacap to buy Boston-area-based CDMO PCI Synthesis. Also in June, Sweden’s Recipharm struck a $60.2 million deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K.

Suggested Articles

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.